Keyword: Shire

AbbVie and Shire investors struck an agreement to settle claims AbbVie misled the public about its reasons for pursuing Shire.

Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.

Takeda’s partnership with Microsoft and Eurodis to take on rare disease delivered initial results this week with a road map to shorten the time to diagnosis.

Novo faces a tough task as several long-acting factor VIII therapies are already on the market, and Roche's antibody drug Hemlibra is zooming ahead.

A jury ordered Takeda, which just scooped up Shire, to pay $155 million for stepping on Bayer's hemophilia patent.

Takeda withdrew an FDA filing for Ninlaro in post-transplant maintenance because it doesn't yet have survival data the agency wants.

Roche has the pipeline it needs for growth, its chairman said, but the company could add on with small- or medium-sized M&A.

Emerging markets have been holding Takeda back, despite double-digit growth in China. Now, the company could reap some cash by selling some of those products.

Pharma is too preoccupied with short-term growth, so it's going the easier me-too route rather than focusing on "transformative" therapies, the CEO said.

FiercePharma’s most-read headlines of 2018 include industry themes that dominated the year's news or return time and again—and, of course, scandals.